265 results on '"Bone, H-G"'
Search Results
2. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis
3. Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation
4. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
5. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial
6. Effects of Hemoglobin in Sepsis
7. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate
8. Improved adherence with PTH(1–84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis
9. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials
10. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass
11. Prävention, Diagnose, Therapie und Nachsorge der Sepsis: Erste Revision der S2k-Leitlinien der Deutschen Sepsis-Gesellschaft e.V. (DSG) und der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI)
12. Diagnose und Therapie der Sepsis: S-2 Leitlinien der Deutschen Sepsis-Gesellschaft e. V. (DSG) und der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI) *: Teil 2
13. Einsatz von Ketamin bei Sepsis und systemischen Entzündungsreaktionen
14. Diagnose und Therapie der Sepsis: S-2 Leitlinien der Deutschen Sepsis-Gesellschaft e.V. (DSG) und der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI)*
15. Diagnose und Therapie der Sepsis: S-2 Leitlinien der Deutschen Sepsis-Gesellschaft e. V. (DSG) und der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI)*: Teil 1
16. Diagnose und Therapie der Sepsis: S2-Leitlinien der Deutschen Sepsis-Gesellschaft e.V. (DSG) und der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI)
17. Einsatz von Vasopressin und Terlipressin bei Sepsis und systemischen Entzündungsreaktionen: Auswirkungen auf Mikrozirkulation, Sauerstofftransport, Metabolismus und Organfunktion
18. Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI))
19. Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis
20. An Open-Label Extension Study of Alendronate Treatment in Elderly Women with Osteoporosis
21. Die venöse paradoxe Luftembolie
22. Sauerstoffangebot in der Sepsis Seit 10 Jahren mehr Fragen als Antworten: Seit 10 Jahren mehr Fragen als Antworten
23. Comparison of the haemodynamic effects of nitric oxide synthase inhibition and nitric oxide scavenging in endotoxaemic sheep
24. Ersticken
25. Abstracts from the symposium on recent advances in Paget’s disease of bone and related bone diseases
26. Terlipressin in patients with septic shock: friend or foe?
27. Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial
28. EFFECT OF AIRWAY BLOOD FLOW REDUCTION AFTER SMOKE INHALATION
29. Morbide Adipositas in der Anästhesie und Intensivmedizin.
30. S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge: Langfassung.
31. S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge: Zusammenfassung starker Empfehlungen.
32. The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies
33. Studio randomizzato, placebo-controllo, sull’effetto di denosumab nel trattamento dell’osteoporosi maschile
34. Free Papers
35. Free Papers
36. A Randomized Double-Blind Study of Denosumab Compared with Zoledronic Acid in Postmenopausal Women with Osteoporosis Previously Treated with Oral Bisphosphonate
37. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
38. [Prevention, diagnosis, treatment, and follow-up care of sepsis. First revision of the S2k Guidelines of the German Sepsis Society (DSG) and the German Interdisciplinary Association for Intensive and Emergency Care Medicine (DIVI)]
39. Prävention, Diagnose, Therapie und Nachsorge der Sepsis : 1. Revision der S-2k Leitlinien der Deutschen Sepsis-Gesellschaft e.V. (DSG) und der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI)
40. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial
41. OP0250 Denosumab Treatment of Postmenopausal Women with Osteoporosis for 7 Years: Clinical Fracture Results from the First 4 Years of the Freedom Extension
42. OP0248 Inhibition of Sclerostin with Romosozumab in Postmenopausal Women with Low Bone Mineral Density: Phase 2 Trial Results
43. Improved adherence with PTH(1–84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis
44. Results from the First Two Years of the FREEDOM Trial Extension
45. Transitioning to Denosumab from Continuous Alendronate Therapy Further Improves BMD in Postmenopausal Women with Osteoporosis
46. A single-arm multicenter proof-of-concept study of denosumab to treat hypercalcemia of malignancy in patients who are refractory to IV bisphosphonates.
47. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials
48. Prävention, Diagnose, Therapie und Nachsorge der Sepsis. 1. Revision der S2k-Leitlinien der Deutschen Sepsis-Gesellschaft e.V. (DSG) und der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI)
49. Prävention, Diagnose, Therapie und Nachsorge der Sepsis
50. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.